[go: up one dir, main page]

WO1997044667A3 - Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells - Google Patents

Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells Download PDF

Info

Publication number
WO1997044667A3
WO1997044667A3 PCT/FR1997/000892 FR9700892W WO9744667A3 WO 1997044667 A3 WO1997044667 A3 WO 1997044667A3 FR 9700892 W FR9700892 W FR 9700892W WO 9744667 A3 WO9744667 A3 WO 9744667A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
specific
lymphocytes
mhc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR1997/000892
Other languages
French (fr)
Other versions
WO1997044667A2 (en
Inventor
Pierre Langlade-Demoyen
Yu-Chun Lone
Philippe Kourilsky
Jean-Pierre Abastado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Institut Pasteur filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to AU30365/97A priority Critical patent/AU3036597A/en
Publication of WO1997044667A2 publication Critical patent/WO1997044667A2/en
Publication of WO1997044667A3 publication Critical patent/WO1997044667A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention features methods for using MHC/peptide complexes. The successful peptide-specific T lymphocyte purification by adsorption on a solid support coupled with a high density of MHC recombinant molecules, charged with a single peptide is disclosed. This method has enabled the isolating, purifying and quantifying of tumoral specific T lymphocytes, from peritoneal exudate and tumor-infiltrating lymphocytes. These purified T lymphocyte populations can be further multiplied in vitro. The resulting cells show a superior cytotoxic activity and an enhanced anti-tumoral action by re-injection in the tumor carrier. This novel approach is important for analysing the T lymphocytes repertoire at the peptide specificity level and to improve novel T lymphocyte adoptive immunotherapy based therapeutic treatments. Further, the MHC/peptide specific complexes can induce or stimulate peptide-specific T lymphocytes. Thus are also disclosed methods to induce cytotoxic T lymphocytes (CTL). These CTL can be used in turn to fight tumoral cell growth in vitro or in vivo. The MHC recombinant molecule charged with a single peptide can be effectively used in polymer form to stimulate specific immune response ex vivo or in vivo after being injected in man or animal.
PCT/FR1997/000892 1996-05-21 1997-05-21 Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells Ceased WO1997044667A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30365/97A AU3036597A (en) 1996-05-21 1997-05-21 Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65192596A 1996-05-21 1996-05-21
US08/651,925 1996-05-21

Publications (2)

Publication Number Publication Date
WO1997044667A2 WO1997044667A2 (en) 1997-11-27
WO1997044667A3 true WO1997044667A3 (en) 1998-03-19

Family

ID=24614802

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1997/000892 Ceased WO1997044667A2 (en) 1996-05-21 1997-05-21 Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells

Country Status (2)

Country Link
AU (1) AU3036597A (en)
WO (1) WO1997044667A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
WO1997035991A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
AU771239C (en) * 1998-09-14 2004-10-14 Soren Buus A method of producing a functional immunoglobulin superfamily protein
IL127331A0 (en) * 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
FR2798128B1 (en) * 1999-09-06 2001-11-16 Inst Nat Sante Rech Med MEANS OF DETECTION AND PURIFICATION OF T CD8 + LYMPHOCYTE POPULATIONS SPECIFIC TO PEPTIDES PRESENT IN THE HLA CONTEXT
US20040209314A1 (en) 1999-09-06 2004-10-21 Institut National De La Sante Et De La Recherche Medicale France Means for detection and purification of CD8+ T lymphocyte populations specific to peptides presented in the context of HLA
EP1103265A1 (en) * 1999-11-15 2001-05-30 Leids Universitair Medisch Centrum T-cells specific for polymorphic proteins on malignant cells
EP1377609B1 (en) * 2001-03-14 2015-06-24 Dako Denmark A/S Mhc molecule constructs and their uses for diagnosis and therapy
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
CA2357906A1 (en) * 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
JP2006524991A (en) 2003-05-08 2006-11-09 エクサイト セラピーズ インコーポレーティッド Method for producing and isolating antigen-specific T cells
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (en) 2008-02-28 2019-09-09 Dako Denmark As MHC multimers for Borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
MX2011006755A (en) * 2008-12-24 2011-07-20 Oncotherapy Science Inc C1orf59 peptides and vaccines including the same.
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
WO2022046675A1 (en) * 2020-08-23 2022-03-03 Applied Stemcell, Inc. Hla-f-modified cells and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023067A1 (en) * 1993-03-31 1994-10-13 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
WO1995033995A1 (en) * 1994-06-06 1995-12-14 Gti Method and kit for detecting antibodies
WO1995035500A1 (en) * 1994-06-17 1995-12-28 Ludwig Institute For Cancer Research Method for producing cytolytic t cells specific for a complex of peptide and mhc-molecule
WO1996005287A1 (en) * 1994-08-09 1996-02-22 Anergen, Inc. A method for the isolation of t cells from peripheral blood
WO1996026962A1 (en) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Mhc-antigen complexes for detecting and purifying antigen-specific t cells
WO1996036881A2 (en) * 1995-05-16 1996-11-21 Cancer Research Campaign Technology Limited Screening for inhibitors of tcr-mhc interactions

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023067A1 (en) * 1993-03-31 1994-10-13 Abbott Laboratories Tumor-associated antigens recognized by t cells and the uses of these antigens
WO1995033995A1 (en) * 1994-06-06 1995-12-14 Gti Method and kit for detecting antibodies
WO1995035500A1 (en) * 1994-06-17 1995-12-28 Ludwig Institute For Cancer Research Method for producing cytolytic t cells specific for a complex of peptide and mhc-molecule
WO1996005287A1 (en) * 1994-08-09 1996-02-22 Anergen, Inc. A method for the isolation of t cells from peripheral blood
WO1996026962A1 (en) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Mhc-antigen complexes for detecting and purifying antigen-specific t cells
WO1996036881A2 (en) * 1995-05-16 1996-11-21 Cancer Research Campaign Technology Limited Screening for inhibitors of tcr-mhc interactions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
F. GODEAU ET AL.: "Purification and ligand binding of a soluble class I major histocompatibility complex molecule consisting of the first three domains of H-2Kd fused to beta2-microglobulin expressed in the baculovirus-insect cell system.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 5, 1992, pages 24223 - 24229, XP002051156 *
TOSHITANI, KOJI ET AL: "Expression of a single chain HLA class I molecule in a human cell line: presentation of exogenous peptide and processed antigen to cytotoxic T lymphocytes", PROC. NATL. ACAD. SCI. U. S. A. (1996), 93(1), 236-40 CODEN: PNASA6;ISSN: 0027-8424, XP002051157 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Also Published As

Publication number Publication date
AU3036597A (en) 1997-12-09
WO1997044667A2 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
WO1997044667A3 (en) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
Tang et al. T cell exhaustion and CAR‐T immunotherapy in hematological malignancies
Miller et al. Role of monocytes in the expansion of human activated natural killer cells
JP2540544B2 (en) Method for producing lymphokine-activated killer cells
CN103232973B (en) A kind of K562 cell amplification activates the method for NK cell
EP0937251A4 (en) PURIFICATION OF ANTIGEN-SPECIFIC T CELLS
CA2205430C (en) Method for making a medicament for treating secondary immunodeficiency
Ram et al. In vivo transfer of the human interleukin-2 gene: negative tumoricidal results in experimental brain tumors: Case report
Xv et al. Mesenchymal stem cells moderate immune response of type 1 diabetes
US20070172947A1 (en) Methods and compositions for expanding T regulatory cells
JP2002510655A (en) Method of inhibiting mesenchymal stem cell T cell response as immunosuppressant and its use
KR20160093090A (en) Compositions for treating an arthritic condition
Xu et al. A limited course of soluble CD83 delays acute cellular rejection of MHC‐mismatched mouse skin allografts
Chen et al. Effects of IL‐10‐and FasL‐overexpressing dendritic cells on liver transplantation tolerance in a heterotopic liver transplantation rat model
CN102027104A (en) Method for production of cell mass containing cytokine-induced killer cell
Oberholtzer et al. Adoptive transfer of regulatory immune cells in organ transplantation
Wan et al. The potential of regulatory T cell-based therapies for alopecia areata
Morgan et al. Induction of IL-1 secretion from human monocytes by Fc region subfragments of human IgG1.
Morgan et al. Human C3a-mediated suppression of the immune response. I. Suppression of murine in vitro antibody responses occurs through the generation of nonspecific Lyt-2+ suppressor T cell.
Elkins et al. Constitutive production of a factor supporting B lymphocyte differentiation by a T cell hybridoma.
Lindemann et al. Lymphokine activated killer cells
Yu et al. Prolonged survival time of allografts by the oral administration of RDP58 linked to the cholera toxin B subunit
Dumont Therapeutic potential of IL-10 and its viral homologues: an update
CN112941030B (en) Antigen specific Treg and preparation method and application thereof
Marín et al. Potential of tolerogenic dendritic cells in transplantation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97541722

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase